Google
BMY 株価分析 — Bristol-Myers Squibb Company (Healthcare >> Drug Manufacturers - General)
BMY に関するよくある質問
BMYのPER（株価収益率）は？
Bristol-Myers Squibb Company（BMY）は現在PER 14.37倍で取引されています。
BMYのROE（自己資本利益率）は？
Bristol-Myers Squibb CompanyのROEは41.59%です。
BMYの配当利回りは？
Bristol-Myers Squibb Companyの配当利回りは3.87%です。
BMYの品質スコア（Quality Score）は？
当社のAIはBMYの総合財務品質を100点中62点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
BMYは今が買い時ですか？
当社AIのタイミングスコアは100点中91点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
BMYはどのセクターに属しますか？
Bristol-Myers Squibb CompanyはHealthcare >> Drug Manufacturers - Generalセクターに分類されます（NYSE市場）
BMY AI Analysis Summary
Our AI summary for BMY: Bristol-Myers Squibb Company (NYSE), Healthcare >> Drug Manufacturers - General sector. The stock currently trades at a P/E of 14.37, ROE of 41.59%, a dividend yield of 3.87%. Its financial Quality Score stands at 62/100 — mid-range fundamentals relative to the market. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 65.31
Price
0.45
(0.69%)
Day Change
|
|
|---|
BMY, ファンダメンタルスコアはok ( ファンダメンタル = 62) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
ROEの伸びが低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is good , ...
| Deepscope 分析 |
|
50% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 89 |
| Magic Formula Rank by ROA |
718
|
| Magic Formula Rank by ROE |
718
|
| Magic Formula Rank by ROIC |
728
|
| Price | 65.31 |
| PBV / Sector |
5.98 / 2.68
|
| Earning Per Share | 4.55 |
| PE / Sector |
14.37 / 27.65
|
| PEG or PE/Growth / Sector |
-0.12 / 0.28
|
| Average 1M Daily Value |
563.28 M
|
| Average 1W Daily Value |
637.38 M
|
| Timing Factors |
|
85% |
| Financial Health |
|
47% |
| ポイントになる統計 |
|
70% |
| 配当 |
|
83% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:34 |
| Symbol | BMY |
| Name | BRISTOL-MYERS SQUIBB COMPANY |
| Sector | Healthcare >> Drug Manufacturers - General |
| Market | NYSE |
| Listed Shares | 2,042.07 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 133,367.67 / 256,404.20 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Route 206 & Province Line Road, Princeton, NJ, United States, 08543
Phone: 609 252 4621
Website: https://www.bms.com
Employees: 32,500
Description: Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - General
Click a bubble to view stock details · Bubble size represents market capitalization share
